$9.52
6.67%
Nasdaq, Wed, Sep 24 2025

ChromaDex Corporation Stock price

$9.52
-0.51 5.08% 1M
+1.92 25.26% 6M
+4.22 79.45% YTD
+5.74 151.85% 1Y
+8.33 700.00% 3Y
+5.51 137.41% 5Y
+8.24 643.75% 10Y
+5.77 153.87% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
-0.68 6.67%

Key metrics

Basic
Market capitalization
$759.3m
Enterprise Value
$698.9m
Net debt
positive
Cash
$60.3m
Shares outstanding
79.6m
Valuation (TTM | estimate)
P/E
45.3 | 64.8
P/S
6.5 | 5.9
EV/Sales
6.0 | 5.4
EV/FCF
33.4
P/B
11.8
Financial Health
Equity Ratio
67.5%
Return on Equity
18.6%
ROCE
24.1%
ROIC
93.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$116.3m | $128.5m
EBITDA
$17.5m | $13.3m
EBIT
$16.7m | $10.8m
Net Income
$17.7m | $11.7m
Free Cash Flow
$20.9m
Growth (TTM | estimate)
Revenue
35.9% | 29.1%
EBITDA
1,355.4% | 55.8%
EBIT
823.2% | 39.6%
Net Income
1,413.3% | 36.7%
Free Cash Flow
2,035.7%
Margin (TTM | estimate)
Gross
63.6%
EBITDA
15.0% | 10.4%
EBIT
14.3%
Net
15.2% | 9.1%
Free Cash Flow
18.0%
More
EPS
$0.2
FCF per Share
$0.3
Short interest
4.2%
Employees
-
Rev per Employee
-
Show more

Is ChromaDex Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

ChromaDex Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a ChromaDex Corporation forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a ChromaDex Corporation forecast:

Buy
91%
Hold
9%

Financial data from ChromaDex Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
116 116
36% 36%
100%
- Direct Costs 42 42
26% 26%
36%
74 74
42% 42%
64%
- Selling and Administrative Expenses 52 52
7% 7%
45%
- Research and Development Expense 5.43 5.43
7% 7%
5%
17 17
1,355% 1,355%
15%
- Depreciation and Amortization 0.78 0.78
14% 14%
1%
EBIT (Operating Income) EBIT 17 17
823% 823%
14%
Net Profit 18 18
1,413% 1,413%
15%

In millions USD.

Don't miss a Thing! We will send you all news about ChromaDex Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Chromadex Corp. is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Los Angeles, CA.

Head office United States
CEO Robert Fried
Founded 1999
Website www.niagenbioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today